Class III Medical Devices
PMA is FDA's most rigorous premarket pathway — reserved for Class III devices where no valid predicate exists and risk cannot be mitigated by general or special controls alone. Success requires clinical evidence, organizational discipline, and FDA engagement strategy that begins years before submission.
Discuss Your PMA StrategyUnderstanding PMA
Premarket Approval (PMA) is governed by Section 515 of the FD&C Act and 21 CFR Part 814. It applies to Class III devices — those that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. Unlike the 510(k) pathway, PMA requires proof of safety and effectiveness, not merely substantial equivalence to an existing device. This is a fundamentally different evidentiary standard.
The most common Class III devices requiring PMA include implantable cardiac devices, certain orthopedic implants, novel diagnostic platforms, and devices treating life-threatening conditions without adequate prior art. If your device was initially classified as Class III through the 1976 Medical Device Amendments and has not been reclassified, PMA is required regardless of how similar it is to other marketed devices — unless a De Novo grant has since established predicates for the device type.
FDA accepts two primary PMA formats: Traditional PMA, submitted as a complete package once all data is available, and Modular PMA, which allows submission of non-clinical, manufacturing, and clinical modules in sequence as data becomes available. The modular approach is generally preferred for complex devices where the clinical program runs over multiple years — it allows FDA review of completed modules to begin while later modules are still in development, potentially reducing total review time.
The decision between modular and traditional filing should be made early in device development, in consultation with FDA through Pre-PMA meetings. FDA's CDRH has specific guidance on when modular submissions are appropriate and how modules should be structured. We work with sponsors to develop the filing strategy, Pre-PMA meeting agenda, and module development timeline at the outset of the program — not after the clinical trial has already been designed.
PMA clinical evidence must demonstrate reasonable assurance of safety and effectiveness — a standard that in practice requires well-controlled clinical trials with clinically meaningful endpoints. The study design (randomized controlled trial vs. single-arm with objective performance criteria, superiority vs. non-inferiority, primary vs. co-primary endpoints) is a scientific and regulatory decision that will be scrutinized by FDA reviewers and, if an advisory panel is convened, by a panel of independent clinical experts.
We work with sponsors at the IDE stage to design clinical programs that address FDA's expected questions: Is the patient population representative? Are the endpoints clinically meaningful and objectively measurable? Is the follow-up duration adequate to characterize the device's risk-benefit profile? What are the statistical analysis plan requirements? Poor study design is the leading cause of PMA approval failure — and it cannot be remediated after the trial has concluded.
PMA approval is not the end of the regulatory program — it is the beginning of post-approval obligations. FDA approval orders may include conditions such as post-approval studies (PAS), annual reports, labeling restrictions, and use restrictions. Significant changes to an approved PMA device — design changes, manufacturing process changes, labeling changes — require PMA supplements, ranging from 30-day notices to full panel-track supplements requiring advisory panel review. We build post-approval planning into every PMA engagement from the start.
A 510(k) demonstrates substantial equivalence to a predicate device. A PMA demonstrates safety and effectiveness based on the device's own clinical data — a higher evidentiary standard required for Class III devices. PMA involves a clinical advisory panel review for most devices.
FDA's performance goal for a complete PMA is a decision within 180 days of filing. Most PMAs take 12–24 months from submission to approval, accounting for deficiency responses and advisory panel meetings. We build realistic timeline expectations into your development program from day one.
FDA expects at least one well-controlled clinical study under an approved IDE. Endpoint selection and follow-up duration are device-specific — we develop the clinical strategy in advance through Pre-Submission meetings to reduce review-cycle risk.
Get Started
PMA programs take years and millions of dollars. The decisions made in the first 90 days — pathway, study design, Pre-PMA strategy — determine whether the program succeeds. Talk to us before those decisions are locked in.